Drug Database
OC

octreotide

✓ Approved

TTY Biopharm · SSTR2 · 小分子

什么是 octreotide?

octreotide 是一种小分子,由TTY Biopharm研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

公司TTY Biopharm
药物类别小分子, 多肽类
分子靶点SSTR2, SSTR5
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

作用机制

分子靶点

octreotide 作用于 2 个分子靶点:

SSTR2somatostatin receptor 2 (SST2)
SSTR5somatostatin receptor 5 (SST5, SS-5-R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

octreotide 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Endocrine disordersAcromegaly✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Pancreatic neuroendocrine tumour metastatic✓ Approved

相关研究文献

PubMedBMC gastroenterology2026-11-19

Precision liver surgery-guided anatomical yttrium-90 radiation segmentectomy with resin microspheres for hepatocellular carcinoma.

Zhou Zheyu Z, Huang Xin X, Liang Ziwei Z, Feng Xiaobin X et al.

For patients with early-stage hepatocellular carcinoma (HCC), radiation segmentectomy (RS) has been recognized as a curative-intent treatment option. Besides, real-world experience has suggested that RS may achieve favorable local tumor control in appropriately selected patients with large or advanced HCC. However, standardized and widely accepted procedural protocols for anatomical RS have yet to be established. We proposed an anatomical RS paradigm guided by precision liver surgery principles. Clinical, imaging, and follow-up data were retrospectively reviewed for HCC patients who underwent RS at our institution between Oct 2022 and Jun 2025. Treatment response was assessed on contrast-enhanced CT/MRI using the Liver Imaging Reporting and Data System Treatment Response Algorithm (LI-RADS TRA). Hematologic and liver function-related biochemical toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Time-to-progression (TTP) and overall survival (OS) were estimated using the Kaplan-Meier (K-M) method. Twenty-three HCC patients were included; 11 received RS alone (Cohort 1) and 12 received RS combined with systemic therapy (Cohort 2). The absorbed dose to target lesions was 250.0 (200.0-300.0) Gy. Among patients with tumors < 5 cm, radiation subsegmentectomy (sub-RS) was achieved in 9 of 17 (52.9%). The objective response rate (ORR) for target lesions was 100% at both 3 and 6 months. All patients were discharged uneventfully, and 87.0% (20/23) were discharged on post-procedure day 1. Grade 3 adverse events consisted of lymphopenia (n = 7) and alanine aminotransferase elevation (n = 1); all were considered treatment-related. The median follow-up time for the overall cohort was 18.8 months. The median TTP was 32.7 months for Cohort 2, whereas the median OS was not reached in either cohort. Precision liver surgery-guided anatomical RS using resin microspheres appears feasible and well tolerated, with favorable early tumor control in selected HCC patients.

PMID 43052788
阅读全文 →
PubMedJournal of medical imaging and radiation sciences2026-11-18

The role of 18F-AlF-NOTA-octreotide PET/CT in assessing recurrent carotid body paraganglioma and peptide receptor radionuclide therapy eligibility: A case report.

Loureiro Marilack Viana D Assunção Marques MVDAM, Felix Renata Christian Martins RCM

Paragangliomas (PGLs) are a rare class of neuroendocrine tumors arising from the autonomic nervous system ganglia, which may be either parasympathetic or sympathetic. We present the case of a 49-year-old female patient with a history of cervicalgia and paroxysmal adrenergic symptoms. Her medical history included surgical resection of functional bilateral carotid body PGLs (Shamblin III on the right and Shamblin II on the left), as well as a positive family history of PGL. Cervical magnetic resonance imaging showed no evidence of lesions. However, ¹¹¹In-octreotide scintigraphy revealed a discrete focal area of abnormal radiotracer uptake on the left side of the neck. Further evaluation with Al¹⁸F-1,4,7-triazacyclononane-1,4,7-triacetate-octreotide (¹⁸F-AlF-NOTA-octreotide) PET/CT identified three hypermetabolic cervical foci. Despite its rarity, PGL should never be excluded from the differential diagnosis when clinical symptoms and diagnostic findings are consistent with its etiology. This report serves as a reminder that rare diagnoses deserve consideration and contributes an additional case of PGL to the current literature.

PMID 43050738
阅读全文 →
PubMedThe Annals of pharmacotherapy2026-11-18

Reply: "Impact of Duration of Intravenous Octreotide Infusion on Achieving Hemostasis in Patients With Acute Variceal Hemorrhage".

Pham Tien T, Yerke Jason J, Rudoni Michael M, Kapoor Aanchal A et al.

PMID 43046683
阅读全文 →
PubMedAnalytical chemistry2026-11-18

Versatile Dual-Chiral Covalent Organic Framework Microspheres Synthesized at Room Temperature for Chromatographic Separation and Raman Detection of Chiral Polar Compounds.

Huang Simin S, Xia Ling L, Li Gongke G

Chiral separation and detection remain challenging areas in analytical science. Herein, we report a mild and rapid preparation of versatile dual-chiral covalent organic framework (D-CCOF) microspheres that can be directly employed as both a chiral stationary phase and a Raman substrate for the chiral separation and detection of polar chiral compounds. Based on the rapid synthesis of three-component COF microspheres at room temperature, uniform D-CCOF microspheres were prepared through two-step mild post-modification, including an ultraviolet-assisted thiol-ene click reaction for precise chiral site modification. The integration of two chiral functional groups (thiolated β-cyclodextrin and glutathione) into the skeleton of COF with low energy consumption provided abundant chiral sites. When employed as a chiral stationary phase in HPLC, D-CCOF demonstrated enantioseparation performance for hydroxyl-containing drug intermediates that was superior to that of single-chiral COFs and comparable to that of commercial chiral columns. D-CCOF was also used as a Raman chiral substrate for the detection of six carboxyl-containing chiral metabolites by monitoring the intensity ratio variations of two characteristic Raman bands at ∼1133 and ∼1146 cm-1. Furthermore, it demonstrated the potential for chiral qualitative analysis in complex matrices. Molecular simulations revealed that the interactions between the two chiral groups on the dual-chiral COF and the enantiomers are dominated by hydrogen bonds and van der Waals interactions and that the synergistic effect of the dual chiral groups contributes to chiral recognition. This work offers a green and facile route to the rapid synthesis of dual-chiral COF microspheres and illustrates the potential of this dual-chirality design for both chromatographic enantioseparation and Raman-based chiral detection.

PMID 43046369
阅读全文 →
PubMedZhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery2026-11-18

[Effect of sustained-release gelatin methacryloyl hydrogel microspheres loaded with neural stem cells and neurotrophin 3 for repairing spinal cord injury in rats].

Cai Manqi M, Qin Jinyu J, Lin Baoyi B, Li Xinpeng X et al.

To construct sustained-release gelatin methacryloyl (GelMA) hydrogel microspheres loaded with neural stem cells (NSCs) and neurotrophin 3 (NT-3), and to investigate their roles and underlying mechanisms in spinal cord injury (SCI) repair through both in vitro and in vivo experiments. Hydrogels with different degrees of methacrylation (GelMA-30, GelMA-60, GelMA-PR) containing NT-3, as well as GelMA-30 hydrogel microspheres, were prepared. Their micromorphology and pore size were characterized by scanning electron microscopy; porosity, swelling ratio, in vitro degradation, and sustained-release capacity were measured for material characterization. NSCs from Sprague-Dawley (SD) rats were co-cultured with hydrogels of varying methacrylation degrees, concentrations, or morphological forms. Cell compatibility was assessed using the cell counting kit 8 (CCK-8) and live/dead cell staining. Based on uniform pore structure, moderate swelling ratio, in vitro release performance, and cell viability, the optimal hydrogel material for NSCs loading was selected for subsequent experiments. In vitro, NSCs without hydrogel were served as the control group. The effects of the prepared hydrogel/microspheres on NSCs proliferation, apoptosis, and differentiation were evaluated by EdU staining, propidium iodide (PI) staining, Annexin Ⅴ/PI staining, and immunostaining for neural differentiation markers-glial fibrillary acidic protein (GFAP), myelin basic protein (MBP), and neuronal class Ⅲ β-tubulin (TUJ-1). Forty 8-week-old female SD rats were randomly divided into sham-operation, SCI, hydrogel, and microsphere groups. The sham-operation group underwent only laminectomy without spinal cord injury; the other groups received T10 SCI modeling, after which the hydrogel and microsphere groups received a 10 μL transplantation of the respective hydrogel into the lesion area. Within 8 weeks after operation, the Basso-Beattie-Bresnahan (BBB) scale was assessed weekly to evaluate motor function recovery, and footprint analysis was performed at 8 weeks. Spinal cord tissues were harvested for histological and immunofluorescence staining (GFAP, MBP, TUJ-1, Ki67) to assess the effects on motor function and neural regeneration/repair. Expressions of GFAP, MBP, and TUJ-1 were detected by Western blot and real-time fluorescence quantitative PCR (qRT-PCR). Furthermore, transcriptome sequencing was performed to compare gene expression differences between the hydrogel and microsphere groups. Scanning electron microscopy showed that all hydrogels possessed porous structures, with the microspheres exhibiting larger pore sizes and higher porosity and swelling ratios than the other hydrogels. In vitro experiments demonstrated that all materials maintained stable mass within 28 days and had favorable sustained-release profiles, with the microspheres reaching a cumulative release rate of 90% at 5 days. Cell compatibility assays revealed that NSCs remained highly viable in all hydrogels, and the 5.0%GelMA-30 microspheres showed the highest cell viability (P<0.05). Based on these material characterizations, the 5.0%GelMA-30 hydrogel/microspheres were selected for further experiments. In vitro experiment showed that, compared with the hydrogel group, the microsphere group exhibited superior promotion of NSCs proliferation and differentiation toward neurons and oligodendrocytes, while more effectively inhibiting astrocytic differentiation (P<0.05). In vivo experiments indicated that both the hydrogel and microsphere groups promoted motor function recovery in SCI rats, with the microsphere group showing significantly better recovery (P<0.05). Histological analysis revealed a smaller cavitation area in the microsphere group than in the hydrogel group, and Ki67 staining further confirmed stronger NSCs proliferative activity in the microsphere group (P<0.05). Western blot and qRT-PCR results were consistent, showing that the microsphere group enhanced neural and myelin regeneration and inhibited glial scar formation (P<0.05). Transcriptome sequencing analysis revealed more differentially expressed genes in the microsphere group compared with the hydrogel group, with 74 upregulated and 31 downregulated genes, suggesting that the sustained-release hydrogel microspheres may exert their reparative effects during SCI repair through regulation of multiple gene expressions. The GelMA-30 sustained-release hydrogel microspheres exhibit good biocompatibility and sustained drug release performance. They promote structural repair and functional recovery after SCI by regulating multiple gene expressions.

PMID 43046572
阅读全文 →
PubMedFrontiers in bioengineering and biotechnology2026-11-18

Advances in injectable liposome-microspheres platforms for osteoarthritis therapy: from sustained delivery to multifunctional disease modification.

Atawula Abudukaisaier A, Zhang Xinrui X, Wu Chuanlong C, Chen Zhijie Z et al.

Osteoarthritis (OA) is a chronic, whole-joint disorder marked by progressive cartilage degradation, subchondral bone remodeling, synovial inflammation, and capsular fibrosis, affecting over 500 million individuals worldwide. Current pharmacotherapies are mainly palliative, with no approved disease-modifying osteoarthritis drugs (DMOADs). Intra-articular (IA) injection provides direct joint access but is hampered by rapid drug clearance and short residence times. Injectable liposome-microsphere (iLMP) systems have recently emerged as integrative delivery platforms that synergistically combine the high loading capacity, targeting versatility, and stimuli-responsiveness of liposomes with the sustained release, lubrication, mechanical support, and protective shielding of hydrogel microspheres. This "nano-in-micro" hierarchical architecture enables prolonged joint retention, spatiotemporally controlled drug release, active cell/tissue targeting, and even gene editing, thereby shifting OA management from symptom alleviation toward true disease modification. In this review, we systematically examine the rational design of iLMPs, covering liposomal composition and functionalization, microsphere fabrication technologies (microfluidics, electrospraying, 3D bioprinting, emulsification), and assembly strategies (embedding, anchoring, adsorption, and matrix hybridization). We then detail their physicochemical determinants-size, surface charge, rheology, and degradation kinetics-and discuss the multifaceted therapeutic mechanisms, including sustained pharmacokinetic modulation, boundary lubrication, active/passive targeting, enzyme/ROS/pH-responsive release, nucleic acid delivery, and exosome-hybrid biofunctionalization. Finally, we critically analyze current translational barriers (scale-up, long-term stability, safety, and cost) and outline future directions toward intelligent, personalized, and combination regimens. With continued advances in biomaterials, microengineering, and precision medicine, iLMPs are poised to become a cornerstone of next-generation OA therapy.

PMID 43048464
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多octreotide